Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Announces Earnings Results

by · The Cerbat Gem

Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($2.23) EPS for the quarter, Zacks reports.

Here are the key takeaways from Valion Bio, Inc. Common Stock’s conference call:

  • Valion Bio highlighted a major regulatory milestone for Entolimod: NIAID provided the first FDA-precedent gastrointestinal study protocol and will fully fund the BLA-enabling in vivo program, shifting the Animal Rule pathway to a federally supported effort.
  • Management said Velocity Bioworks is now operational, with roughly 45 employees on site and a successful 200-fold manufacturing scale-up completed on time and within budget, positioning it as the company’s nearest-term revenue opportunity.
  • The company reiterated that Entolimod has broad government interest, including briefings with the U.S. Department of War and a request for information from Ukraine, which management says supports its potential use as a medical countermeasure for acute radiation syndrome.
  • Valion Bio outlined a longer-term push into oncology supportive care, with physician-sponsored neutropenia studies expected to begin in the second half of 2026 and six institutional sites already expressing interest.
  • First-quarter financials showed higher spending after the company’s biopharma pivot, with operating expenses rising to $5.6 million, net loss widening to $6.2 million, and cash falling to $7.2 million from $12.6 million at year-end, underscoring continued financing needs.

Valion Bio, Inc. Common Stock Price Performance

Valion Bio, Inc. Common Stock stock traded down $0.04 during trading hours on Thursday, hitting $0.93. The stock had a trading volume of 150,725 shares, compared to its average volume of 238,158. The company has a debt-to-equity ratio of 0.38, a current ratio of 20.13 and a quick ratio of 20.13. The stock has a market capitalization of $2.92 million, a price-to-earnings ratio of -0.14 and a beta of 1.86. Valion Bio, Inc. Common Stock has a 1-year low of $0.72 and a 1-year high of $5.60. The stock’s fifty day moving average is $1.01 and its two-hundred day moving average is $1.38.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a report on Monday, April 20th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Read Our Latest Analysis on Valion Bio, Inc. Common Stock

Valion Bio, Inc. Common Stock Company Profile

(Get Free Report)

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.

Read More